Neurological features of Fabry disease: Clinical, pathophysiological aspects and therapy

A. Bersano, S. Lanfranconi, C. Valcarenghi, N. Bresolin, G. Micieli, P. Baron

Research output: Contribution to journalArticlepeer-review


Fabry disease is a multisystem, Xlinked, lysosomal storage disorder caused by a mutation in the GLA gene on chromosome Xq22 resulting in alphagalactosidase A enzyme (αGal A) deficiency. Neurological manifestations other than cerebrovascular accidents include small fibre neuropathy and dysautonomic disorders, which may be the presenting clinical features in a proportion of patients. An atypical disease onset may be misdiagnosed until the emergence of a more typical clinical picture, characterized by chronic renal and cardiac failure. Thus, neurologists should consider Fabry disease in differential diagnosis and provide an appropriate diagnostic work up. This review focuses on central and peripheral nervous system involving available diagnostic tools and diagnostic work up in Fabry disease. It also covers the most recent evidence regarding enzyme replacement therapy.

Original languageEnglish
Pages (from-to)77-97
Number of pages21
JournalActa Neurologica Scandinavica
Issue number2
Publication statusPublished - Aug 2012


  • Enzyme replacement therapy
  • Fabry disease
  • Neurological aspects
  • Neuropathy
  • Stroke

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology


Dive into the research topics of 'Neurological features of Fabry disease: Clinical, pathophysiological aspects and therapy'. Together they form a unique fingerprint.

Cite this